// App-Quantinova.ai

Abstract 11216 : Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Chronic Kidney Disease in the National Health and Nutrition Examination Survey (NHANES) 2017-2018 Data

Researchers

Presenter

  • Joanna Huang

Principal Investigators

  • Juan Jose Garcia Sanchez

  • Stephen Nolan

  • John Guzek

  • Lise Retat

  • Laura Webber

  • Anjay Rastogi

Medical Centers

  • Health Economics, BioPharmaceuticals Med, AstraZeneca, Cambridge, United Kingdom

  • HealthLumen London United Kingdom

  • Division of Rheumatology, Department of Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA

  • BioPharmaceuticals Med, AstraZeneca, Wilmington, DE

  • GMA Diabetes, BioPharmaceuticals Med, AstraZeneca, Cambridge, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Chronic kidney disease

Biomarkers

  • N/A

Drug/Treatment

  • Dapagliflozin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved